
Opinion|Videos|July 2, 2024
Going Beyond Topical Steroids and Calcineurin Inhibitors for AD Treatment
The panel examines the evolution of atopic dermatitis (AD) treatment beyond topical steroids and calcineurin inhibitors, while evaluating the safety and efficacy of a specific topical therapy in AD management.
Advertisement
Episodes in this series

- Based on your experience, how have topical treatments evolved beyond the use of topical steroids and topical calcineurin inhibitors?
- When it comes to topical ruxolitinib, how do you balance the efficacy versus the safety when deciding to treat patients with it?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
5 Consequences If ACA Premium Subsidies End in 2026
2
Stereotactic Body Radiation Therapy Equally Effective as Surgery in Stage I NSCLC
3
New PBM Laws Seek to Protect Independent Pharmacies but Could Raise Costs, Limit Patient Access
4
Measles Outbreaks Cause Financial, Public Health Burden in US
5














































